Status: Not yet recruiting

Phase 2 Trial Of Sacituzumab Tirumotecan For Treatment Of Refractory Metastatic Or Unresectable Squamous Cell Carcinoma Of The Anus/Rectum

To look at the effectiveness of sacituzumab tirumotecan (MK-2870) in treating participants with treatment-refractory unresectable and/or metastatic anal/rectal cancer.

Participants needed: 20

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Oct 2, 2026Locations: 1

Eligibility criteria

Participants must have histologically or cytologically confirmed squamous cell c... [+25]

Has a history of documented severe dry eye syndrome, severe Meibomian gland dise... [+21]

Status: Not yet recruiting

Randomized Phase 2 Study Of Epcoritamab Vs Watch And Wait InPatients With Previously Untreated Low Tumor Burden FollicularLymphoma

To compare the time to next treatment between patients with previously untreated, low tumor burden FL who receive the study drug epcoritamab versus those who do not receive epcoritamab and are monitored only.

Participants needed: 40

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Sep 23, 2026Locations: 1

Eligibility criteria

Histologically diagnosed follicular lymphoma grade 1-3a [+27]

Known active central nervous system lymphoma or leptomeningeal disease [+20]

Status: Recruiting

A Phase 2 Study of Radiotherapy-induced Immune Priming to Enhance Elranatamab (Elra) in Relapsed Refractory Multiple Myeloma (RRMM) With Extramedullary Disease (EMD) and Paramedullary Disease (PMD) "PRIME-EMD-PMD"

To learn if low doses of radiation therapy can help the drug elranatamab enhance the killing effect of the cancer cells.

Participants needed: 34

Trial details

Phase: Phase 2Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Sep 18, 2026Locations: 1

Eligibility criteria

Relapsed disease: progressive disease (PD) >60 days after cessation of prior the... [+16]

Within 14 days or at least 5 half-lives, whichever is less, of any investigation... [+16]

Status: Recruiting

Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma

To learn if zanzalintinib and pembrolizumab can help to control select subtypes of advanced/metastatic soft-tissue sarcoma (UPS, MFS, HGPS, and HGUS

Participants needed: 20

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: Aug 20, 2026Locations: 1

Eligibility criteria

Participants must have histologically or cytologically confirmed undifferentiate... [+16]

Prior treatment with immune checkpoint inhibitors (ICIs) [+46]

Status: Not yet recruiting

Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial

To learn whether certain blood and imaging tests can show which people with early-stage TNBC may already have had a complete response to chemotherapy before they go to surgery.

Participants needed: 200

Trial details

Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: M.D. Anderson Cancer CenterUpdated: May 28, 2026Locations: 1

Eligibility criteria

Participants must be 18 years of age or older, able to understand and give writt... [+11]

Stage IV (metastatic) breast cancer [+7]